Radionuclide therapy

Click here to load reader

  • date post

  • Category


  • view

  • download


Embed Size (px)


8. Radionuclide therapy. Principles of radionuclide therapy “ . - PowerPoint PPT Presentation

Transcript of Radionuclide therapy


8Radionuclide therapy

1The therapeutic use of radiopharmaceuticals is based on the concept of selective localization of radiopharmaceuticals coupled with the lethality of the same because of the tissue damage resulting from highly ionizing particulate emissions such as particles.Principles of radionuclide therapy 2Principles of radionuclide therapy The radionuclide has to be concentrated at the site of the abnormality (tumor) with minimal injury to the normal tissues

A variety of approaches to this problem is possible

1- Element e.g. I-131, P-32, Sr-892-Metabolic agents, e.g. I-131 MIBG3-Labeled antibodies4-Labeled cell5- Direct administration into the cavities3Tissue factors affecting rardiopharmaceutical uptake

1- blood perfusion 2-exravascular space 3-interstitial pressure

Reduction in blood flow causes -Less radiopharmaceutical is supplied to the viable cell -Hypoxic state of the cells reduces the effect of the radiation (Hypoxic cells are resistant)4Principles of radionuclide therapy

1-Radiopharmaceutical uptake (%) 2-Quantity of radiopharmaceutical 3-Retention of radiopharmaceutical 4-Physical half-life- Too short will not take full advantages of the time in the tissue- Long time gives unnecessary radiation dose to normal tissues

5-Non-homogenous uptake reduces local absorbed dose

6-selectivety of radiopharmaceutical (target to non target)5Radionuclides therapy

ParticleAlpha emitters ( short range: 50 m) rarely usedBeta emitters (I-131, P-32,Sr-89; range few mm) most commonly used

Gamma rays (I-125)6



9 * Thyroid I-131 Radionuclide therapy Thyrotoxicosis Differentiated thyroid cancers * P-32 therapy in myeloproliferative diseases Polycycemia rubra vera * MIBG therapy neuroblastomaand phaeochromocytomaand

* Therapeutic use of radiolabelled antibodies (Target)

* Palliation of bone pain (Strontium-89 and Smarium-153) bone metastases of breast and prostate 10Alternative approaches to targeting therapy

Injection into serous cavities-Intra-peleural therapy-Intra-peritoneal cavity -Intra-articular therapy-Direct intra-cystic injection11The thyroid Thyrotoxicosis Differentiated thyroid cancers RAI I-131 Half life 8 Principal gamma energies 360keV Principal beta Emax 0.6 MeV In the past 60 years many patients through out the world have received treatment for both thyrotoxicosisand thyroid carcinoma and the cumulative experience with this form of radionuclide therapy has confirmed its safety and efficacy12Therapy of thyrotoxicosis1-Medical2-Surgery3-RAI

Causes of ThyrotoxicosisDiffuse toxic goiter (Graves disease)Multinodular goiter (Plummers disease)Toxic autonomous nodule 13Practical aspects of RAI therapy in thyrotoxicosis Before RI therapy it is essential that :1-the diagnosis of thyrotoxicosis has been confirmed both clinically and biochemically (hormonal assay T3,T4,and TSH)

2-The use of radionuclide scan in the diagnosis of patients with thyrotoxicosis is very important: a-It confirms the nature of the thyrotoxicosis b- Gravesdisease versus multinodular goiter Plummers disease c- % thyroid uptake

14RAI therapy for thyrotoxicosis General consensus* It is an appropriate treatment for men and women of the middle age upwards (not usually preferred in young age)

*There is no demonstrable risk associated with RAIadministration

*No increased incidence of leukemia and thyroid malignancies * No increased incidence of genetic defects in children born to women and man treated with RAI15Importance of RAI therapy in thyrotoxicosis

Radioiodine would appear from all available data to be safe of treatment in all patients groups including:women of child-bearing years and children but excluding women who arepregnant and breastfeedingPrior to RAI therapy in thyrotoxicosis -Generally elderly patients with thyrotoxicosis should be rendered euthyroid prior to therapy to avoid unpleasant exacerbation of thyrotoxicosis-Prior to RI therapy antithyroiddrug should be discontinued for several days to ensure adequate trapping of RAI16Treatment dose, radiation dose and outcome

The usual administrated dose ranges from 10mCi-20mCi (adult dose 10 mCi)

The radiation dose received by family members is low but itis proportional to the close contacttime such as meal times, car travel and sleeping in a double bed

The incidence of hypothyroidism in the first year ranges between 10-25% with an annual increment, depending on the amount of the administrated dose17Side effects of RI treatment

-Hypothyroidism-Exacerbation of thyrotoxicosis at 7-10 days following RAI administration-Sialitis( the symptoms are usually short lived)-Alterations in taste-Radioiodine is not contra indicated in patients with dysthyroid eye disease18Thyroid carcinoma


* Well Differentiated thyroid Carcinoma (WDTC) Papillary Follicular mixed Papillary and Follicular *Anaplastic ( 5%) *Medullary (10%)

- WDTC in general take up RAI -Nodal metastases are presented at diagnosis in 36% of patients with papillary ca and 13% of patients with follicular ca- Distant metastases were associated with 4% of papillary ca and 16% of follicular ca19 Treatment of thyroid cancer Surgery total or near total thyroidectomyFollowing surgical treatment RAI is the essential treatment

RI has three major roles:- Diagnosis- Ablation- Treatment20Diagnosis

The initial diagnostic approach following surgery is the demonstration of residual normal thyroid tissuefollowing the removal of thyroid tumor Thyroid whole body iodine scans is performed to localize remnant thyroid tissue

Thyroid remnant ablationSubsequent administration of therapy doses will be more effective if all normal thyroid tissue is ablated

The ablation doses are between 30-200mCi21

22- Patients should be hospitalized into a special room until the level of activity fall below that permitted for discharge

- Following ablation the patient should be maintained on thyroxine replacement treatment

- Six months after thyroxine should be discontinued and the patient is reevaluated with I-131 whole body scan

- If recurrent is demonstrated the patient should be admitted for a therapy doseof RAI23- The therapy dose will usually vary from 150-200mCi of RAI

- After treatment the patient returned back on thyroxine replacement therapy

- A repeat scan will be performed following an interval of 6-12months

- Further therapy is given when necessary 24Side effects of radioiodinetherapy

-Nausea-Radiation thyroiditis-Acute and/or chronic sialadenitis-Oligospermiaor azoospermia(70%)-There are no reports in the literature of infertility, or congenital abnormalities in children treated with RAI for thyroid carcinoma25Thank you and Good LuckProf. Dr. Omar Shebl Zahra26